Entero Therapeutics (ENTO) Competitors $0.45 +0.04 (+10.70%) As of 11:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ENTO vs. INDP, SLXN, GELS, APLM, NEUP, TRAW, RLMD, AIM, ACXP, and TSBXShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Indaptus Therapeutics (INDP), Silexion Therapeutics (SLXN), Gelteq (GELS), Apollomics (APLM), Neuphoria Therapeutics Inc. - Common Stock (NEUP), Traws Pharma (TRAW), Relmada Therapeutics (RLMD), AIM ImmunoTech (AIM), Acurx Pharmaceuticals (ACXP), and Turnstone Biologics (TSBX). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. Indaptus Therapeutics Silexion Therapeutics Gelteq Apollomics Neuphoria Therapeutics Inc. - Common Stock Traws Pharma Relmada Therapeutics AIM ImmunoTech Acurx Pharmaceuticals Turnstone Biologics Entero Therapeutics (NASDAQ:ENTO) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and community ranking. Does the MarketBeat Community prefer ENTO or INDP? Indaptus Therapeutics received 13 more outperform votes than Entero Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformEntero TherapeuticsN/AN/AIndaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33% Which has more volatility and risk, ENTO or INDP? Entero Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Indaptus Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Is ENTO or INDP more profitable? Entero Therapeutics' return on equity of -87.06% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Entero TherapeuticsN/A -87.06% -12.01% Indaptus Therapeutics N/A -177.27%-141.06% Do institutionals and insiders believe in ENTO or INDP? 12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 0.5% of Entero Therapeutics shares are owned by insiders. Comparatively, 29.5% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts prefer ENTO or INDP? Indaptus Therapeutics has a consensus target price of $8.50, indicating a potential upside of 1,474.07%. Given Indaptus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Indaptus Therapeutics is more favorable than Entero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor ENTO or INDP? In the previous week, Entero Therapeutics had 3 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 3 mentions for Entero Therapeutics and 0 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.63 beat Entero Therapeutics' score of 0.29 indicating that Indaptus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Entero Therapeutics Neutral Indaptus Therapeutics Positive Which has preferable valuation and earnings, ENTO or INDP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntero TherapeuticsN/AN/A-$15.80MN/AN/AIndaptus TherapeuticsN/AN/A-$15.42M-$1.62-0.33 SummaryIndaptus Therapeutics beats Entero Therapeutics on 8 of the 12 factors compared between the two stocks. Remove Ads Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.95M$6.76B$5.55B$7.86BDividend YieldN/A2.81%5.35%4.04%P/E RatioN/A7.0923.4218.67Price / SalesN/A199.58363.7787.31Price / CashN/A65.6738.1634.64Price / Book0.185.966.614.09Net Income-$15.80M$142.11M$3.20B$246.93M7 Day Performance-29.19%-7.58%-5.01%-3.84%1 Month Performance-17.12%-12.54%-1.58%-7.28%1 Year PerformanceN/A-13.53%8.59%-0.70% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero Therapeutics0.6862 of 5 stars$0.45+10.7%N/AN/A$2.16MN/A0.009Short Interest ↑News CoverageINDPIndaptus Therapeutics3.4467 of 5 stars$0.71+8.0%$8.50+1,092.1%-78.1%$10.29MN/A-0.426Gap DownHigh Trading VolumeSLXNSilexion TherapeuticsN/A$1.19+6.3%$5.00+320.2%N/A$10.01MN/A0.00N/AGap UpGELSGelteqN/A$1.06+1.4%N/AN/A$10.00MN/A0.00N/AAPLMApollomics2.5608 of 5 stars$9.10-4.2%$200.00+2,097.8%-89.8%$9.89M$1.22M0.0045Gap UpNEUPNeuphoria Therapeutics Inc. - Common Stock1.0872 of 5 stars$5.52+2.2%$21.00+280.4%N/A$9.70M$662,715.000.00N/ATRAWTraws Pharma1.2092 of 5 stars$2.65-6.7%N/AN/A$9.68M$226,000.00-0.0217Earnings ReportUpcoming EarningsRLMDRelmada Therapeutics3.8738 of 5 stars$0.32+6.1%$4.25+1,226.5%-94.4%$9.67MN/A-0.1110Earnings ReportGap UpHigh Trading VolumeAIMAIM ImmunoTech2.3772 of 5 stars$0.14-1.9%$2.75+1,897.1%-74.5%$9.47M$190,000.00-0.2920News CoverageACXPAcurx Pharmaceuticals3.4172 of 5 stars$0.43-1.3%$12.00+2,720.2%-83.4%$9.38MN/A-0.393TSBXTurnstone Biologics1.9511 of 5 stars$0.40-1.2%$0.45+11.3%-86.8%$9.35M$19.31M-0.1282Earnings ReportUpcoming EarningsAnalyst Revision Remove Ads Related Companies and Tools Related Companies Indaptus Therapeutics Competitors Silexion Therapeutics Competitors Gelteq Competitors Apollomics Competitors Neuphoria Therapeutics Inc. - Common Stock Competitors Traws Pharma Competitors Relmada Therapeutics Competitors AIM ImmunoTech Competitors Acurx Pharmaceuticals Competitors Turnstone Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTO) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENTO Stock Free ENTO Stock Alerts